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Abstract 
 
We investigate the utility of principal component analysis as a tool for obtaining dose-
volume combinations related to rectal bleeding after radiotherapy for prostate cancer. A 
direct implementation of principal component analysis reduces the number of degrees of 
freedom from the patient’s dose-volume histograms that are associated with bleeding. 
However when low variance principal components are strongly correlated to outcome, 
their interpretation is problematic. A Varimax rotation is employed to aid in 
interpretability of the low variance principal components. This procedure brings us closer 
to finding unique dose-volume combinations related to outcome but reintroduces 
correlation, requiring analysis of the overlap of information contained in such modes. 
Finally, we present examples of cost - benefit analyses for candidate dose-volume 
constraints for use in treatment planning. 
 
PACS: 87.53.Tf 
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Introduction 
 Dose-Volume Histograms (DVHs) are widely used to investigate volume effects in the 
outcome of radiotherapy and play a critical role in treatment planning, where dose-
volume constraints on target and normal tissues ensure safe and efficacious treatment.  
Unique dose-volume combinations that give rise to outcome are difficult to obtain 
directly from statistical analysis of the DVHs of treated patients since the dose-volume 
combinations present in patient populations are correlated with each other. In the context 
of external beam radiotherapy, these correlations arise from the fixed treatment 
techniques and beam geometries used. In this work we employ the well known statistical 
method of Principal Component Analysis (PCA) (Krzanowski 2000) as a means to 
investigate the information contained in dose-volume histograms. The method is applied 
to the analysis of rectal bleeding using the dose-volume histograms of patients receiving 
3D-conformal radiation therapy for prostate cancer at Memorial Sloan-Kettering Cancer 
Center (Bauer et al. 2004) Recently, Dawson et al. have applied PCA to analysis of RILD 
in patients treated with radiotherapy for tumors in the liver (Dawson et al 2005). 
We find that when PCA is applied straightforwardly, it allows us to produce models 
of patient outcome that contain only a small number of uncorrelated degrees of freedom. 
These explanatory variables for outcome consist of projections of the DVH data onto 
particular basis vectors produced by the PCA procedure. This direct implementation of 
the PCA method forfeits ease of interpretation; the modes produced still cannot be simply 
interpreted as representing unique dose-volume combinations correlated to outcome; 
although insight into the qualities of the DVHs that correlate with outcome may be 
ascertained. This potential shortcoming of PCA should not be surprising. PCA partitions 
the data by variance using linear combinations of “original” variables, in this case the 
volumes-exposed. The contribution of volumes-exposed in the various principal 
components is determined by the size of their variance and the redundancy of the 
information they contain, and the association of these qualities with outcome is not 
always straightforward. 
We subsequently employ a Varimax Rotation (Harmon 1970). The Varimax Rotation 
is an orthogonal rotation applied to a truncated set of principal components (consisting of 
the smallest set whose combined variance constitutes the vast majority of the total). Its 
application is an attempt to obtain modes that are simple to interpret. The simplicity of a 
Varimax mode is characterized by non-negligible amplitude in only narrow dose regions. 
Despite the orthogonality of the Varimax modes, the projection of the DVH data onto 
them results in explanatory variables that are once again correlated (Joliffe 1995). Thus, 
when ease of interpretability is obtained by the Varimax Rotation technique, one must 
consider the relationship of the Varimax variables to each other when determining their 
relationship to outcome. 
 
1. Method 
We illustrate our method with data from patients treated for prostate cancer to 70.2 
Gy and 75.6 Gy with 3D-Conformal Radiation Therapy (3D-CRT) discussed in previous 
work (Skwarchuk 2000, Jackson 2001). We consider the relationship between patient 
DVH and ≥ grade 2 rectal bleeding (outcome) arising from treatment (Lawton 1991). For 
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each dose group, DVHs of the rectal wall defined as extending from the sigmoid colon to 
the anal verge were examined. In the case of patients treated to 75.6 Gy the patient 
sample consists of 36 out of 38 patients who developed rectal bleeding before 30 months 
from the end of treatment and a random sample of 83 out of 192 patients who showed no 
bleeding at this time. For patients treated to 70.2 Gy the analysis utilizes data from13 
patients who developed rectal bleeding before 30 months from the end of treatment and a 
random sample of 39 out of 208 patients without bleeding at this time. We remind the 
reader that a six-field arrangement was used to treat the patients. This arrangement 
consisted of one pair of opposed lateral beams and two pairs of opposed oblique beams, 
resulting in three regions of correlated dose to the rectal wall. The first high dose region 
was contained in the overlap region of all beams, the second intermediate dose region 
was contained in the overlap region of all oblique beams, the third low dose region was 
contained in only one oblique pair (Jackson 2001).  
  
Once the DVHs have been constructed they are imported into MATLAB (The 
Mathworks) in which all mathematical manipulations are performed.  
 
 
1.1 PCA  
PCA is a technique used in multivariate data analysis to reduce the number of 
variables necessary to explain the dispersion in a data set. Given a data set in which the 
variables of interest are statistically correlated, PCA constructs a new set of uncorrelated 
variables via an appropriate linear combination of the original variables. Each of the new 
uncorrelated variables explains a unique portion of the data. Typically only a small subset 
of these variables that explains a majority of the variance in the data are retained. The rest 
account for arbitrarily small variations in the data and are discarded.  
The principal component analysis of the patient data proceeds by forming the mean-
adjusted variance-covariance matrix. The mean-adjusted volume for each dose bin is 
obtained by subtracting the dose-bin mean over all patients from each individual patient’s 
DVH as indicated below.  The covariance matrix C consists of correlations between 
mean-adjusted volumes exposed to a particular dose or greater. 
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In the above equations, !iV is the % volume exposed to dose ≥ α  for patient i, iw  
represents the weight of patient i due to the sampling of the patient population. N pt 
denotes the actual number of patients used and !V  is the mean-volume exposed to dose ≥ 
α. All patients, bleeding and non-bleeding, are included in the above summations. The 
prefactor,
1!pt
pt
N
N
, ensures the appropriate divisor for the correlation matrix when all 
weights are equal.  For the purposes of PCA this prefactor is irrelevant as it serves only as 
an overall scale factor on the variance-covariance matrix. The diagonal elements of C 
represent the variance of the DVH data while the off-diagonal elements represent the 
covariance between volumes. The average volumes  !V  for the 75.6 Gy and 70.2 Gy 
patient data are shown in [1(a)-(b)]  
 
Figure 1(a). Weighted mean DVH of all 75.6 Gy patients. The error bars represent 
the standard deviation at each dose. 
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Figure 1(b). Weighted mean DVH of all 70.2 Gy patients. The error bars represent 
the standard deviation at each dose. 
 
The DVH data for each patient is formed from bins of width  2 Gy; the 75.6 Gy 
patient data is comprised of 41 bins and the 70.2 Gy patient data is comprised of 38 bins. 
For compactness of notation and utility during computations we define a matrix X.  The 
rows of X contain the mean-adjusted DVHs for each patient while the columns indicate 
the doses i.e. Xiα is the volume of patient i exposed to dose ≥ α. We also define a weight 
matrix W: 
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Using these definitions we can write the variance-covariance matrix more compactly. 
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The mean-adjusted variance-covariance matrix for patients treated to 75.6 Gy is shown in 
[2]. The correlated regions are clearly visible in the block structure.  
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Figure (2). Variance-Covariance Matrix of %-Volume Exposed  
 
 
The PCA diagonalizes the matrix C via an orthogonal transformation and produces a 
new coordinate system in which to represent the data, known as the principal 
components. To obtain the principal components we use the MATLAB statistical 
package function pcacov which returns the eigenvalues and normalized eigenvectors of 
the covariance matrix.  
The eigenvalues of C represent the variance explained by each of these new 
variables. The eigenvalues are ranked in descending order and the rank of an eigenvalue 
is used to label its corresponding eigenvector. The eigenvectors define the principal axes; 
these are orthogonal and lie along the directions of sequentially maximal variance of the 
data after all higher variance components have been taken into account. The 38 and 41 
bins of the 70.2 Gy and 75.6 Gy patients respectively yield 38 and 41 sets of eigenvalues 
and eigenvectors respectively.  
We define U as the matrix whose columns are the eigenvectors of C and the matrix 
S=XU. The rows of S correspond to an individual patient’s mean-adjusted DVH in the 
space of the principal components, while the columns of S contain the components of the 
patient DVHs along a particular PC. The projection of a DVH onto a principal 
component is its score on that component. Figures [3(a)-(b)] show a typical mean-
adjusted DVH and the representation of this DVH in the space of principal components. 
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The score plot shown in [3(b)] is typical in that most of the scores beyond the first several 
are near zero indicating that only the first several principal components have utility for 
understanding the structure of the DVH. In our analysis of 3D-CRT DVH data, we retain 
the minimal set of modes required to account for > 99% of the total variance. We also 
include the contribution of a mode toward explaining outcome as an additional criterion 
for retention in the analysis. Once the data is decomposed by variance and the scores 
corresponding to each patient’s projection onto the principal components are obtained, it 
remains to test each set of scores for correlation to bleeding.  
 
Figure 3(a) Typical Mean-Adjusted DVH for a 75.6 Gy patient. 
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Figure 3(b) Scores associated with DVH in [3(a)]. 
 
 
1.2. Logistic Regression  
  Patient scores corresponding to specific principal components are individually 
tested for correlation to rectal bleeding by performing univariate logistic regression (Le 
2003,Kleinbaum 1994, Prentice and Pike 1979, McCullagh and Nelder 1989). A step-
forward procedure is used to build a multivariate model of all scores that contribute to the 
understanding of patient outcome. The bleeding variable for patient i, Yi, is binary and 
has been coded 1 for bleeding patients and 0 for non-bleeding patients. A multivariate 
logistic model provides the probability of bleeding for each patient given the scores of the 
contributing PCs. 
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Siα is the score of patient i on PC α, the β’s are the coefficients obtained from the logistic 
regression. Significance of the scores, or equivalently significance of the mode 
corresponding to the αth principal component, is determined by the p-value of the 
corresponding βα. A particular βα is significant if the probability of obtaining the fit value 
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or greater of !"  is less than or equal to 0.05 under the null hypothesis: βα = 0. As a 
result of the logistic regression, a single number characterizing the bleeding information 
content of each patient’s DVH is obtained:   
!="
#
##$ ii SS .  (6) 
 
Here the sum is carried out over statistically significant components. 
 
1.3 Receiver Operator Characteristic Analysis 
 
 The effectiveness of the numbers S'i in distinguishing bleeding from non-bleeding 
patients in the data set can be obtained through a receiver operator characteristic (ROC) 
analysis (Le 2003, Hanley and McNeill 1982,1983).,For each cutoff value the number of 
true positives, TP, is defined as the number of bleeding patients with a regression model 
value greater than or equal to the cutoff. The true positive rate, TPR, for a particular 
cutoff is the number of true positives divided by the total number of bleeding patients. 
Similarly the number of false positives, FP, is given by the number of non-bleeding 
patients with a regression model value greater than or equal to the cutoff value. The 
corresponding false positive rate, FPR, is given by the number of non-bleeding patients 
with a model value greater than or equal to the chosen cutoff divided by the total number 
of non-bleeding patients. In the ROC analysis, the true positive rate defined for each S'i is 
plotted against the corresponding false positive rate.  
The area under the ROC curve (AUC) is the probability of a random bleeding patient in 
the data having a value of S’ greater than that of a random non-bleeding patient. An 
estimate of the error of the AUC is obtained using the method of Hanley and McNeill 
(1982, 1983). A consistency calculation for the AUC and its error is performed using a 
bootstrap analysis. A full set of bleeders and non-bleeders are randomly selected from 
their respective sample populations with replacement. The covariance matrix is formed 
from these data and a PCA is performed yielding a model of bleeding. The AUC is 
computed by counting the number of pairs for which the model value of a bleeder 
exceeds the model value of a non-bleeder divided by the product of the number of 
bleeders and non-bleeders for each bootstrap configuration i.e. the number of bleeder – 
non-bleeder pairs (Hanley and McNeill 1982). A distribution of areas is obtained from 
which the mean AUC is computed. For each bootstrap configuration the AUC is given 
by: 
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Θ is the Heavyside function and Si , as above, is the model value. The error is computed 
from the standard deviation of the bootstrap areas. 
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1.4 Varimax 
 A well-known limitation of PCA is that the higher order principal component 
eigenvectors are not always easily interpretable. While the eigenvectors of C are 
orthogonal, they are not necessarily sparse; a sparse mode is one with many elements 
near or equal to zero and just a few elements that are large. The eigenvectors oscillate 
with increasing frequency as their order increases leading to difficulty in obtaining 
unique volumes exposed. The Varimax rotation method (Harmon 1970) maximizes the 
sparseness of each of a group of modes by means of an orthogonal rotation. As a result of 
a Varimax rotation, a new set of modes is produced; each of these new modes will have 
few components with large amplitude and many with small or nearly zero amplitude. The 
Varimax procedure is performed on the subspace of PCs necessary to reconstruct the data 
to the determined accuracy and not just those correlated to outcome.   
The Varimax Rotation matrix Rv is obtained by maximizing the combined variance 
of the retained modes, known as the simplicity, given by:  
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Here, N=UR is the eigenvector in the Varimax rotated space, U is the matrix of PCA 
eigenvectors given above, K is the dimension of the eigenvectors (i.e. 41 and 38 for 75.6 
and 70.2 Gy patients respectively), and β indexes the mode in the retained subspace of 
PCA eigenvectors. 
The simplicity is minimal and equal to zero for a set of vectors that has uniform extent 
over its support, i.e. all components of the eigenvectors are equal in magnitude. It is 
maximal for eigenvectors each containing a single non-zero element. The Varimax 
Rotation produces orthogonal modes as can be verified by considering the orthogonality 
relations for the matrices U and Rv.  
However it can be shown that a result of the Varimax Rotation is to reintroduce 
correlations into the Varimax scores which are the projection of the data onto the 
Varimax modes. This may become problematic when using multivariate logistic 
regression for outcome analysis as the explanatory or independent variables are no longer 
uncorrelated possibly confounding their effect on outcome. We will discuss the effects of 
this issue on our analysis in the results section of this paper. 
1.5  Partitioning the bleeding from non-bleeding patients 
If the model derived from PCA is to be of clinical utility we must consider how to 
partition the bleeding patients from the non-bleeding patients. A specific numerical value, 
S'c, or cutoff, separating bleeding from non-bleeding patients must be determined. This 
requires an analysis of the expected cost of misclassifying a patient (Bradley 1997). For 
example, incorrect classification of a non-bleeder as a bleeder might change his treatment 
by underdosing the PTV to avoid complications while incorrectly classifying a bleeder as 
a non-bleeder might result in overdosing the PTV to enhance tumor control resulting in 
severe complication. To determine the cost of such actions would require the 
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contemplation of medical factors beyond the scope of this paper and in general would not 
be a trivial task.  
 
It is instructive to consider a cost function which is the expected cost per patient of false 
positives (FP) and false negatives (FN) combined (Bradley 1997).  
 
)(*)()(*)( FNCFNpFPCFPpCost += .  (9) 
 
The quantities p(FP) and p(FN) are the probabilities of a false positive and a false 
negative respectively. A patient whose model value, S'i, is greater than or equal to the 
cutoff is considered to have a positive test value. Conversely if the patient’s model value 
is less than the cutoff, he is considered to have a negative test value. A false positive 
model value corresponds to a model value for a patient who tests positive for bleeding 
given the chosen cutoff but is in fact a non-bleeding patient. A false negative similarly 
corresponds to a model value for a patient who tests negative for bleeding but is in fact a 
bleeding patient. The cost function may be re-expressed in terms of the true positive rate, 
TPR, the false positive rate, FPR, defined in section III, and the proportion of bleeding in 
the patient population denoted by prop. The proportion of bleeding is given by the 
fraction, appropriately weighted, of bleeding patients in the data set.  
 
)(**)1()(*)1(* FNCpropTPRFPCpropFPRCost !+!= .   (10) 
 
We also consider the predictive values and accuracy of this test. The positive predictive 
value (Le 2003), PPV, of the test, is the probability that a patient is a bleeder conditioned 
on a positive test result. The positive predictive value is a function of the chosen cutoff 
and is the weighted fraction of all positives that are true positives (TP) as determined by 
that cutoff. The negative predictive value (Le 2003), NPV, is the probability that a patient 
is a non-bleeder conditioned on a negative test result; it is the weighted fraction of true 
negatives (TN) determined from that cutoff. The test accuracy or efficiency for a chosen 
cutoff is given by  
)1()1( propFPRpropTPR !"!+"=#    (11) 
and is the proportion of correctly classified patients. The misclassification rate is the 
complement 1- ! . 
 
An optimal cutoff is determined by minimizing the cost. In the simple case of equal costs 
for false positive and false negative test results, the minimum cost analysis for obtaining 
an optimal cutoff for the model reduces to a minimum misclassification analysis of the 
model. 
 
 
2. Results 
 
2.1 PCA 
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 We analyze the DVH data representing the % rectal wall volume exposed to a 
dose ≥ α for the patients having received 75.6 Gy. The proportion of bleeding patients is 
16.5%. The weight associated with a bleeding patient is 1.0556 and the weight associated 
with a non-bleeding patient is 2.3133. The spectrum of eigenvalues obtained by 
diagonalizing the variance-covariance matrix for these data ranked by the size of the 
eigenvalue is shown in [4].  
 
Figure (4). Eigenvalue spectrum of variance-covariance matrix for 75.6 Gy patient 
data. 
 
The first eight eigenvalues account for greater than 99.5% of the variance with the 1st 
mode explaining 85.6% of the total variance in the DVH data. We restrict our analysis to 
only these modes. When each of these eight modes is univariately tested for correlation to 
rectal bleeding, modes 1, 6, and 7 attain significance. Under multivariate analysis only 
modes 1 and 7 survive. Mode 7 only explains 0.3% of the DVH data however the logistic 
regression analysis for this mode clearly indicates it is significant with regards to 
outcome. Thus we obtain a two-mode model of rectal bleeding for the 75.6 Gy patients. 
Modes 1 and 7 are shown in [5(a)] and [5(b)] respectively.  
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Figure 5(a). Principal Component Analysis eigenvector belonging to largest 
eigenvalue for 75.6 Gy patient data. 
 
 15 
 
 
Figure 5(b). Principal Component Analysis eigenvector belonging to 7th largest 
eigenvalue for 75.6 Gy patient data. 
 
 
The mode-1 eigenvector follows the shape of the variance in the % rectal wall 
volumes very closely and can be interpreted as a positive fluctuation of the % volume at 
all doses for bleeding patients versus non-bleeding patients. The information on outcome 
contained in this mode is redundant with the mean dose. Indeed a logistic regression 
model with both mean dose and the scores obtained from mode-1 input as explanatory 
variables indicates that they contain overlapping information with respect outcome. 
Individually each of these variables, mean dose and PC-1, under logistic regression 
analysis attains a p-value << 0.05 while combined they attain p-values >> 0.05. The 
reason for this is almost certainly due to the fact that the mean dose is the integral over 
the DVH with respect to dose which, for discrete DVH data, can be viewed as the 
unweighted sum of volumes-exposed. The DVH is constrained at low dose to be near 
100% and at high dose it must go to 0%. All of the variance in the integral of the DVH 
must stem from the middle range doses. This is precisely the dose region that the first 
mode emphasizes; the volumes with the largest variance and covariance. This result is 
also reminiscent of previous work showing that the mean value of the bleeding patient 
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DVHs is shifted relative to the mean value of the non-bleeding patient DVHs (Skwarchuk 
2000, Jackson 2001). 
As seen in [5(b)], mode-7, on the other hand, is more complicated and does not 
readily lend itself to interpretation. It shows strong fluctuations near 23 - 25 Gy, 41 - 43 
Gy, and 79 Gy. These comprise of two distinctive groupings. Analysis shows that the 
volumesV23, V24, V41, and V43 are all highly correlated, with the correlation between 
V23 and V24 > 0.9, and the correlation between V41 and V43 > 0.9. The inter-group 
correlation, the correlation between V23 and V24 with V41 or V43, is > 0.8. This is 
obtained by computing the linear correlation coefficient. 
VarVar
Cov
ji
ij
ij •
=!   (12) 
The numerator, Covij , represents the correlation, the weighted inner product, of the PCA 
scores corresponding to modes i and j and Vari represents the variance of the score 
corresponding to mode j. The high inter-group correlation between these volumes is a 
result of the beam geometry. The volume V79 has a relatively small variance and is not 
as highly correlated with the other volumes; the correlation coefficient between V79 and 
the V23-V24 is  ≈ 0.2 and the correlation of V79 to V41-V43 is ≈ 0.25.  
 
There are several possible explanations for the structure of mode-7. One is that this PCA 
mode is correlated with outcome due to the influence of V79. Mode-7 is a high-order 
mode, explaining only a small fraction of the variance. V79 has a relatively small 
variance and it is not highly correlated with any of the other volumes as can be observed 
in [2]. One expects the low order, high variance, PCA modes, e.g. mode-1, to be 
dominated by high-variance, strongly correlated volumes. The lower order modes, e.g. 
mode-7, by the definition of PCA, should contain low-variance volumes and account for 
variance not already accounted for in the previous modes. Earlier investigation of this 
data has shown that the volume exposed to high dose, !  V79, is strongly correlated with 
outcome(Jackson 2001). Understanding the role of the other volumes in this mode is 
more difficult. This mode could be revealing a separate contribution to outcome 
fromV42-V43 or V23-V25, in addition to V79. What is clear is that while one might 
obtain or infer insights into the information contained in the DVH from the principal 
component analysis, the procedure does not allow for a definitive statement concerning 
dose-volumes and their unique contribution to outcome when high-order modes attain 
significance.  
 
Despite this difficulty we can construct a model for PCA mode 1 and mode 7, 
Si'=β1Si,1+β7Si,7. The ROC curve of this model is shown in [6]. The AUC for this model, 
computed directly from the TPR, FPR curve, is 0.80 ± 0.05. A ranking of the S'i is shown 
in [7]. The tendency for bleeding patients is to have positive values; the non-bleeding 
patients are more evenly distributed but are relatively rare at the highest model values. 
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Figure 6. Receiver operator characteristic curve – True Positive Rate (TPR) versus False 
Positive Rate (FPR) for 75.6 Gy patient data using PCA modes 1 and 7. The area under 
the curve is 0.80. 
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Figure 7.  Ranked model value from combined 1st and 7th principal component. Bleeding 
patients are represented by open diamonds, non-bleeding patients are represented by 
filled circles. The minimum cost cutoff corresponds to 2.1 on the vertical scale. 
 
2.2 Cost Analysis 
 
Applying the cost analysis method we find the optimal cutoff for the model, We 
consider the case where the costs of false positives and false negatives are set equal to 
unity. In this case the total cost (10) is identically equal to the misclassification rate (11).  
The cost for 75.6 Gy patients is minimized when the FPR = 0.012 and the TPR = 
0.33. This corresponds to a value of '
c
S =2.1 for the two component PCA model. The 
(PPV,NPV) pair obtained at this value of '
c
S  is (0.85,0.88). For these values of FPR and 
TPR the efficiency of the test is 88%; and hence the misclassification rate is 12%. The 
inability of the model to more accurately classify patient outcome is largely due to the 
entanglement of the bleeding and non-bleeding patient DVH data and is intrinsic to the 
data set. The TPR is only 33% at the cutoff. This analysis minimizes the false positives as 
one would expect for a relatively low prevalence complication.  
An estimate of the errors in this analysis is obtained using a leave-one-out cross-
validation. Each patient in turn is left out of the construction of the variance-covariance 
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matrix and PCA analysis is performed. The left-out patient’s value for the model is then 
predicted. Using all the predicted values a new ROC is formed with an AUC = 0.78. This 
is well within the stated error of the original AUC. The cost analysis is used on the cross-
validated data to produce a new cutoff. We determine the FPR, TPR, PVP, and NPV 
values corresponding to this cutoff as well as the misclassification rate. The calculated 
values corresponding to the cross-validated data are essentially unchanged from the 
estimates based on the original data set. 
Figure [8] shows the Cost, TPR, FPR, PPV, and NPV for this model. The cost 
initially decreases with FPR and flattens at model values !  1.8.The relative rates of 
decrease of FPR and TPR control the cost. In [7] it is noticed that as the cutoff value 
increases, fewer non-bleeders are incorrectly classified. When the model value S’=1.8 is 
attained, all but one non-bleeder is correctly classified. Further increase in the cutoff 
results in a rapid decrease in the TPR and a slow decrease in the FPR until it becomes 
zero.  The PPV is bound from below by the proportion of bleeders which in this case is 
equal to 0.165. The NPV is bound from below by the proportion of non-bleeders which is 
equal to 0.835. As stated earlier, the chosen cutoff is dependent on the relative costs 
associated with false positives and false negatives. The proportion of bleeding patients to 
non-bleeding patients, i.e. prop to (1-prop), is about 0.2 indicating the ratio of false 
negatives to false positive costs would need to become large to have an impact on the 
chosen cutoff.  
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Figure 8. Cost analysis for 75.6 Gy patient data. The vertical dotted line indicates the 
minimum cost values for TPR, FPR, PVP, and NPV. The dots represent actual values 
while the lines serve as a guide. The vertical line indicates the minimum cost values of 
the displayed quantities. 
 
2 .3 Varimax Rotation 
 
Applying the Varimax Rotation to the 1st eight retained modes, we find three 
Varimax modes are significant with respect to outcome. These modes are labeled mode-
2, mode-5, and mode-6 due to their order on return from the Varimax routine; as 
explained, the Varimax procedure introduces correlation between the modes thus the 
individual variance of the modes no longer plays a unique role in identifying them. 
Modes-2, 5 and 6 are shown in [9 (a)-(c)].The ROC curve for a model produced from 
these three modes, [10], yields the same AUC as the ordinary PCA modes, 0.80 ± 0.05. 
The utility of Varimax modes is that only small regions of each mode are large. We 
notice there is no appreciable amplitude for doses < 40 Gy in any of the modes. Varimax 
mode-6 clearly represents a contribution from the 77 - 79 Gy dose bins to rectal bleeding. 
Mode-2 is peaked near 47- 49 Gy and mode-5 near 73 Gy indicating contributions from 
those doses respectively are increasing the probability of bleeding. The minimum cost 
analysis yields TPR=0.25, FPR=0.012, S'c = 2.5. The PPV and NPV for this model are 
0.80 and 0.87 respectively The misclassification rate is approximately 13%. The Varimax 
procedure incurs an expense of an additional degree of freedom as compared with a 
simple application of the PCA method for the 75.6 Gy patient data.  
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Figure 9(a). Varimax mode 2 for 75.6 Gy patient data showing strong amplitude in the 
47-47 Gy region of dose. 
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Figure 9(b). Varimax mode 5 for 75.6 Gy patient data showing strong amplitude in the 73 
Gy dose region. 
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Figure 9(c). Varimax mode 6 for the 75.6 Gy patient data showing strong amplitude in 
the 77 - 79 Gy dose region. 
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Figure 10.  Receiver Operator Characteristic Curves for 75.6 Gy data set: 3-mode 
Varimax model (filled circles) AUC=0.80, 2-mode Varimax model (triangles) 
AUC=0.76.  
 
We address the correlation between the Varimax scores by computing their linear 
correlation coefficient.. The relevant correlations are: ρ26=-0.42, ρ25=-0.93, ρ56=0.53 
where the subscripts refer to the Varimax modes. Clearly the correlation between scores 2 
and 5 is so great that there is redundant information included in the model when both 
modes are kept and one can question whether they both belong in the model. In point of 
fact V73 is highly correlated with V47. Mode 5, the least significant under univariate 
analysis, enters the multivariate model last and only becomes significant in the presence 
of modes 2 and 6. If it is removed from the model we obtain an AUC = 0.76±0.05. This 
AUC is not discernable from the full 3-mode model given the errors. The correlation 
between mode-2 and mode-6 is < 0.5 and we may reasonably use these two modes in the 
model. Thus the 2-mode model constructed from Varimax mode 2 in combination with 
Varimax mode 6 could reasonably be used instead of the full 3-mode model although we 
may be losing some separation power in distinguishing bleeders from non-bleeders. 
Using the minimum cost analysis, the 2-mode model produces a PPV = 0.79, and a  NPV 
= 0.87. At the minimum cost point the misclassification rate is 14%; the TPR and FPR is 
22% and 1.2% respectively. The score values produced from the two-mode Varimax 
model for each patient are shown in [11].  
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Figure 11. Ranked Varimax model coefficients for the 75.6 Gy patients: 2-mode 
model. Bleeders are represented by open diamonds. Non-bleeders are represented by 
filled circles. 
 
The 2-and 3-mode models do not differ greatly in their predictive capability. In such 
cases we can question whether the information in the discarded mode is pertinent to 
outcome and if the explanatory value of the model has become compromised. Without 
more data we are not able to make more of a statement as to whether the 2- or 3-mode 
model is more useful in partitioning the outcome.  
 
In addition to the % volume exposed for patients treated to 75.6 Gy, we have 
analyzed the % volume exposed data for patients treated to 70.2 Gy. These patients 
comprise a much smaller data set than the 75.6 Gy patients. A total of 52 patients are 
included with only 13 bleeding patients. The non-bleeding patients carry a weight of 
5.3333 while the weight of a bleeding patient is 1.0. For these data the first eight modes 
account for 99.75% of the total variance, however only the first PC correlates 
significantly with rectal bleeding. This mode is shown in [12] and much like the 75.6 Gy 
data it reflects a net positive % volume fluctuation of bleeders with respect to non-
bleeders at all doses. This mode explains nearly 87% of the variance for the 70.2 Gy 
patients’ DVH data. In a similar fashion to the 1st PCA mode of the 75.6 Gy analysis, this 
mode contains information with respect to outcome analogous to the mean dose. An ROC 
 26 
analysis of the model composed of only this one mode yields an AUC = 0.73 ± 0.09, 
[13]. Figure [14] shows the ranked 70.2 model values using the single significant mode. 
Given the distribution of the bleeders, their weights and the very low prevalence for 
bleeding,  6%, the cost function fails to find a suitable cutoff in the data.  
Applying the Varimax procedure we find that a single Varimax mode peaked near 39 
Gy is significant for correlation to rectal bleeding. This mode is shown in [15]. An ROC 
analysis of this mode gives an AUC = 0.76± 0.09. Only a single Varimax mode is 
contributing to outcome, confounding is therefore not a problem for this patient data set.  
 
Figure 12. PCA  mode-1 corresponding to the largest eigenvalue for the 70.2 Gy data set. 
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Figure 13. ROC curve for 70.2 Gy patient set based on model from largest PC –
AUC=0.73. 
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Figure 14.  Ranked model value from 1st  principal component for 70.2 Gy data. Bleeding 
patients are represented by open diamonds, non-bleeding patients are represented by 
closed circles.  
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Figure 15. Varimax mode 6 for 70.2 Gy patient data. 
 
3. Discussion and Conclusion 
 
 
The PCA clearly shows us the strong correlations among the DVH variables, and 
emphasizes the difficulty of extracting unique dose volume combinations from clinical 
data such as ours. Additional techniques such as Varimax can only partially resolve these 
problems. Combination of our data with additional clinical data from complimentary 
treatments with a different pattern of correlations among dose volume variables may be 
the only way to fully resolve these issues.  
 
 
The PCA analysis presented in this work on the MSKCC 3D-CRT patient data shows that 
a reduction in the number of degrees of freedom needed to describe outcome from the 
dose-volume histograms can be attained. One can use this reduction to form simple 
models relating outcome to the DVH. The 1st eigenvalue in the 75.6 Gy and 70.2 Gy data 
show common characteristics: a positive fluctuation across the entire DVH (see [5(a)] 
and [12]) and is related to variance in the mean dose. Higher order modes have more 
problematic interpretation as they oscillate wildly (see e.g. [5(b)]). Although the modes 
are uncorrelated with each other, and outcome models can be built from them, they do 
not allow us to clearly deduce unique DVH constraints for clinical use; although insight 
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into information contained in the DVHs may be inferred. We find that the variance in the 
DVH and outcome are not necessarily simply related. This is evident by the fact that the 
1st PC is strongly related to outcome but one does not find additional correlation with 
outcome, in the 75.6 Gy data, in the subsequent modes until mode-7. Additionally we 
find that PC mode-6 is borderline and attains significance, in addition to modes 1 and 7, 
when particular patient data is excluded in a leave-one-out analysis or when a bootstrap 
analysis is performed. An analysis of the entirety of the data set, as presented, does not 
include mode-6 in the multivariate model.    
 
The Varimax rotation brings us one step closer to our overall goal of deducing unique 
DVH constraints for clinical use. The Varimax modes are obtained by an orthogonal  
rotation of the PCA basis functions but now the support of each mode is maximally 
concentrated in one region of dose. Unfortunately the Varimax modes are once again 
correlated with each other; careful inspection of these modes is necessary to assess their 
independent value.  
 
To deduce DVH constraints for use in treatment planning, one further step is required, a 
cost analysis of the consequences of imposing candidate DVH constraints. The cost 
analysis presented here (for purposes of illustrating our method) assumed that the cost of 
false positives and false negatives was equal. In reality a full analysis of these costs must 
take into account the likelihood and consequence of underdosing the tumor, in addition to 
the likelihood of rectal bleeding.  
 
In this analysis, we used prostate DVHs, where the treatment plans are standardized and 
have applied each of our analyses to DVHs with one prescription dose. In the case of 
patients treated to different prescription doses or where the DVHs do not have the same 
regularities, for example Lung DVHs from non-small-cell lung cancer patients, we do not 
expect the PCA and Varimax analyses to give such concentration of variance in 
individual modes. 
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